Last updated on August 2019

A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)


Brief description of study

The purpose of the study is to evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).

 

Clinical Study Identifier: TX227900

Find a site near you

Start Over

University of South Florida-Morsani College of Medicine

13330 USF Laurel Dr. Tampa, FL United States
  Connect »